Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03980730 · ClinicalTrials.gov registry record · Phase 2
Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance
A Phase 2 study, sponsored by vTv Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT03980730 is a Phase 2 study that was terminated before completion, run by vTv Therapeutics. The registered enrollment target is 43 participants.
The verdict
NCT03980730, a Phase 2 study, was terminated before completion, sponsored by vTv Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).
Interventions
- DRUG Placebo
- DRUG Azeliragon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2019-06-27 |
| Est. Completion | 2021-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03980730
The ClinicalTrials.gov registry entry for NCT03980730 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is vTv Therapeutics, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03980730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03980730 about?
NCT03980730 is a clinical study titled "Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose Tolerance". This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer's disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient's participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).
What is the current status of trial NCT03980730?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2019-06-27. Estimated completion is 2021-01-29.
What interventions are being tested in trial NCT03980730?
The interventions under investigation include: Placebo (DRUG), Azeliragon (DRUG).
Who is sponsoring clinical trial NCT03980730?
This trial is sponsored by vTv Therapeutics, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.